Aurora Oncology is structured around the development and task of bringing to use-condition biologics developed by the principals for treatment of superficial bladder cancer. Designated DAB389EGF and Nano-EGFR, these work by targeting specific receptors on the surface of cancer cells. Nano-EGFR is also allows for imaging of bladder cancer in the patient. Management indicate that both these products are poised to enter clinical development. Not ths usual type of systemtic company anchored development. Firm was founded in 2011 and subsequently licensed the intellectual property associated with DAB389EGF from the University of Colorado Denver. Major non-dilutive funding (>$2.4M in R43, R44 grants) from the NIH has positioned the principals to begin human clinical trials. The company continues to develop its intellectual property with new provisional patent applications including the incorporation of Dr. Parkâs diagnostic/therapeutic inventions. Aurora Oncology received a grant of $149,040 from Colorado Office of Economic Development and Trade (grant num. 13BGF-12), a grant of $146,880 from NIH/NCI (1R43CA174011-01), a $50,000 equity investment from CID4, and a grant of $50,000 from the Colorado Cancer Translation Research Accelerator. Since funding of the FastTrack SBIR grant, the company has received an additional $115,000 in State funding and a $100,000 grant from the University of Colorado SPARK program. These resources have been used to demonstrate preclinical proof-of-concept with the lead AUR-21 asset, to develop a companion diagnostic, and to enable a credible position to begin the significant fundraising needed to complete IND enabling work and enter the clinic
